Ozempic's Cardiac Benefits Boost Dialysis Providers

Shares of dialysis providers surged as investors focused on the cardiac benefits of Novo Nordisk's diabetes drug Ozempic, following data indicating less impact on chronic kidney disease. The potential for GLP-1 drugs to treat health issues beyond diabetes and obesity also affected shares in bariatric surgery providers, food firms, and glucose-monitoring device makers. DaVita and Fresenius Medical saw significant stock gains, while Novo Nordisk's shares fell. The full results from the trial are awaited later this year to determine the impact on dialysis stocks.